Search results for "uva"

showing 10 items of 2916 documents

Part-time special education predicts students' reading self-concept development

2018

Abstract The academic self-concept changes from childhood to early adulthood in relation to experiences of capability in different school tasks and comparison with peers. Students in special education have a lower academic self-concept than their peers do, but it is unclear how part-time special education affects self-concept development. In Finnish schools, part-time special education is learning support that is usually provided for 1–2 h/week in small groups. The main aim of this study was exploring the effects of participation in part-time special education and gender on the level and change in three academic self-concept domains (General School, Mathematics and Reading) between the ages…

MULTIPLE DIMENSIONSPERCEPTIONSSocial Psychologyminäkuvamedia_common.quotation_subjecteducationlongitudinal researchSelf-conceptCHILDRENAcademic achievementpitkittäistutkimusSpecial educationEducationDevelopmental psychologyerityisopetusPerceptionMultiple time dimensionsACADEMIC-ACHIEVEMENTDevelopmental and Educational Psychologymedicine0501 psychology and cognitive sciencesLearning supportta516Competence (human resources)ESTEEMta515media_common05 social sciences050301 educationCOMPETENCEEFFICACYoppilaatLEARNING-DISABILITIESADOLESCENCEINTERNAL/EXTERNAL FRAMELearning disabilitypart-time special educationmedicine.symptomacademic self-conceptPsychology0503 education050104 developmental & child psychologyLearning and Individual Differences
researchProduct

Two new biologically active triterpene saponins from Acanthophyllum squarrosum.

2000

Two novel triterpenoid saponins (1 and 2) have been isolated from the roots of Acanthophyllum squarrosum. The structures were established mainly by a combination of 2D NMR techniques as 3-O-beta-D-galactopyranosyl-(1-->2)-[beta-D-xylopyranosyl-(1-->3)]-be ta-D-glucuronopyranosylgypsogenin-28-O-beta-D-xylopyranosyl-(1-->3 )-b eta-D-xylopyranosyl-(1-->4)-alpha-L-rhamnopyranosyl-(1-->4)-[alpha-L- rhamnopyranosyl-(1-->3)]-beta-D-fucopyranoside (1) and 3-O-beta-D-glucopyranosylgypsogenin-28-O-alpha-L-rhamnopyranosyl-( 1-- >2)-alpha-L-arabinopyranosyl-(1-->2)-[beta-D-glucopyranosyl-(1-->6 )]- beta-D-glucopyranoside (2). Compound 1 showed a moderate concentration-dependent immunomodulatory effect …

Magnetic Resonance SpectroscopySpectrophotometry InfraredStereochemistryChemical structureMolecular Sequence DataSaponinPharmaceutical SciencePharmacognosySpectrometry Mass Fast Atom BombardmentPlant RootsAnalytical Chemistrychemistry.chemical_compoundTriterpeneAdjuvants ImmunologicDrug DiscoveryLymphocytesOleanolic AcidOleanolic acidPharmacologychemistry.chemical_classificationPlants MedicinalPlant ExtractsHydrolysisOrganic ChemistryGlycosideNuclear magnetic resonance spectroscopySaponinsTerpenoidComplementary and alternative medicinechemistryCarbohydrate SequenceMolecular MedicineCell DivisionJournal of natural products
researchProduct

Chromone and phenanthrene alkaloids from Dennettia tripetala.

2002

Dennettine, a new 2,6-dimethoxychromone and three known phenanthrene alkaloids (uvariopsine, stephenanthrine and argentinine) in addition to the phenolic and known compound vanillin were isolated from the roots of Dennettia tripetala. Their structures were determined by physical and spectroscopical one dimensional (1D) and 2D-NMR analysis, including heteronuclear multiple bond correlation and nuclear Overhauser enhancement spectroscopy.

Magnetic Resonance SpectroscopyTertiary amineStereochemistryAnnonaceaePharmacognosyPlant RootsStephenanthrinechemistry.chemical_compoundAlkaloidsDrug DiscoveryOrganic chemistrySpectroscopyDennettia tripetalabiologyMolecular StructureVanillinUvariopsineGeneral ChemistryGeneral MedicineNuclear magnetic resonance spectroscopyPhenanthrenePhenanthrenesbiology.organism_classificationchemistryHeteronuclear moleculeAnnonaceaeChromonesChromoneChemicalpharmaceutical bulletin
researchProduct

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab pl…

2019

10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC. This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined.…

Male0301 basic medicineCancer ResearchEsophageal NeoplasmsReceptor ErbB-2SURGERYmedicine.medical_treatmentGastroenterologyStudy ProtocolNEOADJUVANT CHEMOTHERAPYAntineoplastic Agents Immunological0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesOXALIPLATINNetherlandsAged 80 and overDOCETAXELMiddle AgedOPEN-LABELlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChemotherapy regimenNeoadjuvant TherapyProgression-Free SurvivalTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleGastro-esophageal junction cancerEsophagogastric JunctionFluorouracilPertuzumabmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsCAPECITABINEAdenocarcinomaAntibodies Monoclonal Humanizedlcsh:RC254-282CapecitabineYoung Adult03 medical and health sciencesBreast cancerStomach NeoplasmsInternal medicineHER2Republic of KoreaREGRESSIONGeneticsmedicineHumansBREAST-CANCERPerioperative PeriodAgedCisplatinChemotherapyPerioperative chemotherapyPertuzumabbusiness.industryTrastuzumabmedicine.diseaseOxaliplatin030104 developmental biologyCisplatinbusinessGastric cancerFollow-Up Studies
researchProduct

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

2018

Abstract Purpose: Nilotinib plus doxorubicin showed to be synergistic regarding apoptosis in several sarcoma cell lines. A phase I/II trial was thus designed to explore the feasibility of nilotinib as coadjuvant of doxorubicin by inhibiting MRP-1/P-gp efflux activity. The phase I part of the study is presented here. Patients and Methods: Nilotinib 400 mg/12 hours was administered in fixed dose from day 1 to 6, and doxorubicin on day 5 of each cycle. Three dose escalation levels for doxorubicin at 60, 65, and 75 mg/m2 were planned. Cycles were repeated every 3 weeks for a total of 4 cycles. Eligible subtypes were retroperitoneal liposarcoma, leiomyosarcoma, and unresectable/metastatic high-g…

Male0301 basic medicineLeiomyosarcomaOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentDrug Evaluation PreclinicalApoptosisLiposarcomaNeutropeniaMice03 medical and health sciences0302 clinical medicineCell Line TumorInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineAnimalsHumansCell ProliferationNeoplasm StagingChemotherapybusiness.industrySarcomamedicine.diseasePyrimidines030104 developmental biologyOncologyNilotinibChemotherapy AdjuvantDoxorubicin030220 oncology & carcinogenesisFemaleSarcomaNeoplasm GradingChondrosarcomabusinessFebrile neutropeniamedicine.drugClinical Cancer Research
researchProduct

Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why?

2018

The potential of preoperative chemotherapy in rectal cancer is the subject of investigation in a number of global randomized trials. In this overview and expert discussion, Professor Cervantes summarizes the findings of numerous Phase II trials testing neoadjuvant chemotherapy. The crucial points in the next phase of trials include: patient selection, whether radiotherapy can be omitted altogether and whether chemotherapy can be used to augment the initial response to chemoradiotherapy. Finally, with the emergence of Magnetic Resonance Tumour Regression Grade a reliable method for assessing response after initial chemoradiotherapy, we ask if this can be used to drive the use of further sele…

Male0301 basic medicineOncologymedicine.medical_specialtyConsensusColorectal cancermedicine.medical_treatmentRisk AssessmentDisease-Free SurvivalSession (web analytics)law.invention03 medical and health sciencesClinical Trials Phase II as Topic0302 clinical medicineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsPreoperative CaremedicineHumansPreoperative chemotherapyChemotherapyProctectomyRectal Neoplasmsbusiness.industryGastroenterologyPrognosismedicine.diseaseMagnetic Resonance ImagingSurvival AnalysisNeoadjuvant TherapyRadiation therapyTreatment Outcome030104 developmental biology030220 oncology & carcinogenesisFemaleAugmentbusinessChemoradiotherapyColorectal Disease
researchProduct

Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer

2020

AbstractImmune suppressing molecule CD73 is overexpressed in various cancers and associated with poor survival. Little is so far known about the predictive value of CD73 in pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to investigate the prognostic significance of CD73 in PDAC. The study material consisted of 110 radically treated patients for PDAC. Tissue microarray blocks were constructed and stained immunohistochemically using CD73 antibody. Staining intensity and numbers of stained tumour cells, inflammatory cells, stroma, and blood vessels were assessed. High-level CD73 expression in tumour cells was positively associated with PD-L1 expression, perineural invas…

Male0301 basic medicinePathologyentsyymitDatabases Factualpancreatic cancerPerineural invasionB7-H1 Antigen0302 clinical medicineRisk FactorsTumor MicroenvironmentMedicine5'-NucleotidasehaimasyöpäAged 80 and overTissue microarraybiologyGeneral MedicineMiddle AgedPrognosisTreatment OutcomesyöpäsolutChemotherapy AdjuvantimmuunijärjestelmäLymphatic Metastasis030220 oncology & carcinogenesisOriginal ArticleFemaleAntibodyCarcinoma Pancreatic DuctalPD-L1Cell typemedicine.medical_specialtyMicroenvironmentGPI-Linked ProteinsRisk AssessmentPancreaticoduodenectomyPathology and Forensic Medicine03 medical and health sciencesLymphocytes Tumor-InfiltratingPancreatectomyImmune systemStromaPancreatic cancerPD-L1Biomarkers TumorHumansMolecular BiologyAgedNeoplasm Stagingbusiness.industryennusteetPancreatic cancerCell Biologymedicine.disease3126 Surgery anesthesiology intensive care radiologymicroenvironmentPancreatic Neoplasms030104 developmental biologybiology.proteinCD73prognosisNeoplasm Gradingbusiness
researchProduct

Downregulation of intratumoral expression of miR-205, miR-200c and miR-125b in primary human cutaneous melanomas predicts shorter survival

2018

AbstractWhile only 15–25 percent of melanoma patients develop distant metastasis and die, this disease is still responsible for the majority of skin cancer-related deaths. The availability of adjuvant therapies makes the selection of high-risk patients essential. We evaluated the intratumoral expression of ten miRNAs in primary melanomas in relation to its ability to predict melanoma survival. To this end, we correlated miRNA expression in 132 cryopreserved primary and metastatic tumors with clinicopathological factors and clinical outcome. We found sequential downregulation of intratumoral expression of miR-125b, miR-182, miR-200c and miR-205 over the full spectrum of melanoma progression.…

Male0301 basic medicineSkin Neoplasmsmedicine.medical_treatmentlcsh:MedicineDown-RegulationDiseaseArticleMetastasisExtracellular matrix03 medical and health sciences0302 clinical medicineDownregulation and upregulationCell MovementmicroRNABiomarkers TumorTumor Cells CulturedmedicineHumansNeoplasm Invasivenesslcsh:ScienceMelanomaAgedCell ProliferationMultidisciplinarybusiness.industryMelanomalcsh:RPrognosismedicine.diseaseIn vitroGene Expression Regulation NeoplasticSurvival RateMicroRNAs030104 developmental biology030220 oncology & carcinogenesisDisease ProgressionCancer researchlcsh:QFemalebusinessAdjuvantFollow-Up StudiesScientific Reports
researchProduct

EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer

2018

Epidermal growth factor receptor (EGFR) gene copy number (GCN) increase is associated with a favorable anti-EGFR antibody treatment response in RAS wild-type metastatic colorectal cancer. However, there are limited and comparative data regarding the EGFR GCN in primary colorectal cancer tumors and corresponding metastases or the effect of anti-EGFR antibody treatment on EGFR GCN in recurrent disease. In addition, little is known about the potential EGFR GCN changes during anti-EGFR therapy in comparison with other treatment regimens. EGFR GCN was analyzed by EGFR immunohistochemistry-guided silver in situ hybridization in primary and corresponding recurrent local or metastatic tumors from 8…

Male0301 basic medicineTime FactorsColorectal cancerBLOCKADEGene DosageCetuximabmedicine.disease_causeAntineoplastic Agents Immunological0302 clinical medicinePREDICTS RESPONSEMedicineHETEROGENEITYBENEFITCopy-number variationEpidermal growth factor receptorIn Situ Hybridization FluorescenceAged 80 and overbiologyPanitumumabvasta-aineetMiddle AgedImmunohistochemistry3. Good healthErbB ReceptorsGene Expression Regulation NeoplasticTreatment OutcomeRAS MUTATIONSChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleKRASAntibodyColorectal NeoplasmsAdultgene copy numbermedicine.drug_classCETUXIMAB THERAPY3122 Cancerssilver in situ hybridizationDown-Regulationcolorectal cancerIn situ hybridizationAdenocarcinomaMonoclonal antibodyta3111Pathology and Forensic MedicineProto-Oncogene Proteins p21(ras)03 medical and health sciencesKRASHumansWILD-TYPEMETAANALYSISAgedRetrospective Studiessyöpähoidotbusiness.industrymedicine.diseaseta3122Blockadeperäsuolisyöpä030104 developmental biologymonoclonal antibodyMutationCancer researchbiology.protein3111 BiomedicineNeoplasm Recurrence Localbusinessepidermal growth factor receptorACQUIRED-RESISTANCEHuman Pathology
researchProduct

Difensil immuno reduces recurrence and severity of tonsillitis in children: A randomized controlled trial

2020

Oral supplements (OS) support the immune system in fighting upper airways infection. This study aimed to analyze the effect of Difensil Immuno (DI) on the recurrence of tonsillitis and fever in children. A multicentric randomized clinical trial was conducted. One-hundred and twenty children with chronic tonsillitis were randomly assigned to group A, B or control. Patients in group A were treated with 10 mL of DI for 90 consecutive days, patients in group B underwent treatment with 15 mL of DI for 45 consecutive days. The following data were collected at baseline (T0), T1 and T2: tonsillitis and fever episodes, tonsillar volume, blood test results. One-way ANOVA was used to analyze within an…

Male0301 basic medicineTonsillitisGalactansSeverity of Illness IndexGroup AGroup Btonsillitislaw.invention0302 clinical medicineRandomized controlled triallawSecondary PreventionChildNutrition and Dieteticsmedicine.diagnostic_testOral supplementVitaminsrespiratory systemLactobacillus acidophilusZincTreatment OutcomeChild PreschoolFemale030211 gastroenterology & hepatologyAnalysis of variancelcsh:Nutrition. Foods and food supplymedicine.medical_specialtyFeverlcsh:TX341-641ArticleSelenium03 medical and health sciencesAdjuvants Immunologicstomatognathic systemSambucus nigraOral supplementsInternal medicinemedicineHumansBlood testImmune stimulationbusiness.industrymedicine.diseaseTreatment030104 developmental biologyImmune systemDietary SupplementsBlood parametersbusinessimmune stimulation; immune system; oral supplement; tonsillitis; treatmentTonsillitiFood Science
researchProduct